# reload+after+2024-01-23 18:43:32.964575
address1§225 Franklin Street
address2§Suite 2100
city§Boston
state§MA
zip§02110
country§United States
phone§857 284 8891
website§https://ateapharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§74
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jean-Pierre  Sommadossi Ph.D.', 'age': 67, 'title': 'Founder, Chairman, CEO & President', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 1098500, 'exercisedValue': 0, 'unexercisedValue': 3466131}, {'maxAge': 1, 'name': 'Ms. Andrea J. Corcoran J.D.', 'age': 61, 'title': 'CFO, Executive VP of Legal & Secretary', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 732446, 'exercisedValue': 0, 'unexercisedValue': 750700}, {'maxAge': 1, 'name': 'Mr. John F. Vavricka', 'age': 59, 'title': 'Chief Commercial Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 581108, 'exercisedValue': 0, 'unexercisedValue': 744450}, {'maxAge': 1, 'name': 'Dr. Janet M. J.  Hammond M.D., Ph.D.', 'age': 63, 'title': 'Chief Development Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 817158, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Maria Arantxa Horga M.D.', 'age': 55, 'title': 'Chief Medical Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 695854, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Wayne  Foster CPA', 'age': 55, 'title': 'Executive VP of Finance & Chief Accounting Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jonae R. Barnes', 'title': 'Senior Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ariyapadi N. Krishnaraj', 'title': 'Vice President of Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adel  Moussa Ph.D.', 'title': 'Executive Vice President of Chemistry', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Xiao-Jian  Zhou Ph.D.', 'title': 'Executive Vice President of Early Stage Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§10
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.137
currency§USD
dateShortInterest§1702598400
forwardEps§-2.82
exchange§NMS
quoteType§EQUITY
shortName§Atea Pharmaceuticals, Inc.
longName§Atea Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1604064600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2b022d91-ddb5-3459-9d51-2eb405756366
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.0
targetLowPrice§2.0
targetMeanPrice§3.0
targetMedianPrice§3.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§2
quickRatio§31.698
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
